<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn></journal-meta><article-meta><article-id pub-id-type="pmid">8494709</article-id><article-id pub-id-type="pmc">1968458</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients with renal cell carcinoma correlate with response.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Martens</surname><given-names>A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Janssen</surname><given-names>R. A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sleijfer</surname><given-names>D. T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Heijn</surname><given-names>A. A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mulder</surname><given-names>N. H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>The</surname><given-names>T. H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>de Leij</surname><given-names>L.</given-names></name></contrib></contrib-group><aff>Department of Clinical Immunology, University Hospital Groningen, The Netherlands.</aff><pub-date pub-type="ppub"><month>5</month><year>1993</year></pub-date><volume>67</volume><issue>5</issue><fpage>1118</fpage><lpage>1121</lpage><abstract><p>Plasma sIl-2R and sCD8 levels of 12 patients with renal cell carcinoma were determined before and during subcutaneous rIl-2 therapy. Patients with a complete/partial remission showed a significantly stronger initial increase of sCD8 compared to patients with stable disease or tumour progression.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00207-0252.tif" xlink:title="scanned-page" xlink:role="1118" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00207-0253.tif" xlink:title="scanned-page" xlink:role="1119" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00207-0254.tif" xlink:title="scanned-page" xlink:role="1120" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00207-0255.tif" xlink:title="scanned-page" xlink:role="1121" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

